SCHEMBL29938283

SCHEMBL29938283

N[C@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 6/20 0.71
▸ ACE P12821 4/20 0.60
▸ OPRM1 P35372 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30011732 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL30010229 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL29511586 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL30011630 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL29938305 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL30011151 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL30010907 1.00 MME (0.71) MMEACEOPRM1
SCHEMBL31025645 0.96 MME (0.64) MMEACE
SCHEMBL31025643 0.96 MME (0.64) MMEACE
SCHEMBL30011237 0.96 MME (0.64) MMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250064996-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. 2025-02-27 — — US disclosed
US-11819556-B2 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2023-11-21 — — US disclosed
US-11707540-B2 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2023-07-25 — — US disclosed
US-20230144360-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. 2023-05-11 — — US disclosed
US-11541134-B1 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2023-01-03 — — US disclosed
US-11497822-B1 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2022-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11497822-B1 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR MME 106/4885ACE 4209/4885OPRM1 2916/4885
US-11819556-B2 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR MME 106/4885ACE 4209/4885OPRM1 2916/4885
US-20250064996-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF TFRC, SLC39A14, EGFR MME 106/4885ACE 4209/4885OPRM1 2916/4885
US-11541134-B1 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR MME 106/4885ACE 4209/4885OPRM1 2916/4885
US-20230144360-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF TFRC, SLC39A14, EGFR MME 106/4885ACE 4209/4885OPRM1 2916/4885
US-11707540-B2 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR MME 106/4885ACE 4209/4885OPRM1 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback